Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...

Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants.

for pembrolizumab (Keytruda ®) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, then continued as adjuvant ...

Head and neck squamous cell carcinoma (HNSCC) represents a significant health concern worldwide as the sixth most common cancer ... PROR)'s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...

About Head and Neck Squamous Cell Carcinoma (HNSCC) Head and Neck Cancer (HNC ... 201 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with R/M HNSCC ...